A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type
Clinical trial NCT02927925 · COMPLETED
Trial details
- NCT number
- NCT02927925
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-14
- Primary completion
- 2020-01-02
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.